US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges
Risdiplam Launch Among 2020 Tests
Executive Summary
Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.